Gerrards Cross (United Kingdom) | Madrid (Spain), 18th February 2016 – People Who (www.peoplewho.co.uk), the European online platform for e-patients, is kicking off 2016 with the launch of its latest illness: atrial fibrillation. In collaboration with Daiichi Sankyo, the digital platform is launching a new space to spread awareness of the illness in the UK and to offer online services to help improve the lives of people affected by atrial fibrillation in any way, whether diagnosed themselves, caring for someone with the illness or just interested in finding out more.
Atrial fibrillation is a common heart rhythm disorder which affects 33.5 million people worldwide: nearly 0.5% of the world’s population. What’s more, here in the UK it affects at least 1 million people, with many more thought to be living with the illness undiagnosed. And while many live with the illness without even realising it, it can lead to serious complications like stroke. But with the right treatment, it’s possible to live well with atrial fibrillation. Raising awareness of the illness is essential to ensure that patients get diagnosed as early as possible, helping them to live better with the illness and avoid its complications.
Atrial fibrillation affects different people in different ways. Some will notice symptoms like palpitations or shortness of breath, whilst in other cases it goes without symptoms. But given that it can lead to serious complications like stroke, it’s essential to be on the lookout. The surest way to identify it as soon as possible it to regularly check your heartbeat for any irregularities. If it’s consistently below 60 or above 100 beats per minute, or beats with an irregular rhythm, you should go to your doctor. A diagnosis of atrial fibrillation can be confirmed by an electrocardiogram (ECG), a test which measures the heart’s beat using electrodes.
The treatment for atrial fibrillation can include rhythm or rate control, to get the heartbeat under control, ablation to stop the abnormal electrical impulses in the heart which cause the illness, and anticoagulants to prevent the blood from clotting, reducing the risk of stroke. Your doctor will examine your particular case and circumstances to decide on the best course of treatment.
People Who’s atrial fibrillation platform has been launched to give people affected by the illness in any way – whether patients or carers – a space to meet others and find trustworthy information about the illness. At www.peoplewho.co.uk/atrialfibrillation they can find:
A Community, where users can meet others in the same situation as them, join groups of users with interests in common and follow the activities of organisations working with patients of atrial fibrillation. They can also ask questions to the community to get answers from other users and from a qualified doctor.
A Magazine with articles about treatments, prevention and new research surrounding atrial fibrillation, all supervised by doctors to ensure it’s accurate and trustworthy. Users can also submit their own stories of atrial fibrillation for publication in the magazine to share what they’ve learned, and read the stories of other users.
And a Control section where patients can keep a record of the food they eat, medication they take and any readings or test results, using this information to keep track of the illness’s progress. They can also produce reports which they can take to their doctor to give them a better idea of the patient’s life outside the surgery and to personalise their treatment.
To launch the platform, People Who have created a short informative video about how the heart works, and how atrial fibrillation is caused. To watch this video and find further information on atrial fibrillation, visit: www.peoplewho.co.uk/atrialfibrillation
Reference: American Heart Association (2013), Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
Charlayne Iwanczuk – Jaime Domingo | firstname.lastname@example.org | +44 (0) 207 193 7986
About People Who: People Who is an online platform dedicated to the everyday lives of people who live with an illness. A place for patients, carers and healthcare organisations. Together, we want to build a society which lives a little better with illness. We’re already online in France, Germany, the UK, Spain and Italy. And soon we’ll be live in the USA, Mexico, Argentina, Colombia, Peru y Chile.
ore information about the product: www.peoplewho.com
More information about the business: www.peoplewhoglobal.com
About Daiichi Sankyo: Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidaemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit: www.daiichisankyo.com.